XL-647 manufacturers
- Tesevatinib
-
- $109.00 / 1mg
-
2025-07-15
- CAS:781613-23-8
- Min. Order:
- Purity: 97.89%
- Supply Ability: 10g
- XL-647
-
- $3.00 / 3KG
-
2019-08-08
- CAS:781613-23-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | XL-647 | | Synonyms: | Tesevatinib;Tesevatinib(XL647);XL-647;N-(3,4-dichloro-2-fluorophenyl)-6-Methoxy-7-(((3aR,6aS)-2-Methyloctahydrocyclopenta[c]pyrrol-5-yl)Methoxy)quinazolin-4-aMine;N-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-4-quinazolinamine;EXEL-7647;XL-647;XL 647;KD-019;Rel-N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-2-methyloctahydrocyclopenta[c]pyrrol-5-yl)methoxy)quinazolin-4-amine | | CAS: | 781613-23-8 | | MF: | C24H25Cl2FN4O2 | | MW: | 491.3853032 | | EINECS: | | | Product Categories: | | | Mol File: | 781613-23-8.mol |  |
| | XL-647 Chemical Properties |
| Boiling point | 567.9±50.0 °C(Predicted) | | density | 1.356 | | storage temp. | Store at -20°C | | solubility | DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml | | form | A solid | | pka | 10.16±0.40(Predicted) | | color | White to off-white | | InChIKey | HVXKQKFEHMGHSL-QKDCVEJENA-N | | SMILES | N(C1C=CC(Cl)=C(Cl)C=1F)C1=NC=NC2C=C(OC[C@H]3C[C@@]4([H])CN(C)C[C@@]4([H])C3)C(OC)=CC1=2 |&1:19,21,27,r| |
| | XL-647 Usage And Synthesis |
| Uses | XL 647 is a potent and selective EGFR phosphorylation inhibitor and may be used in the treatment of patients suffering from lung cancer. Orally available, multi-target tyrosine kinase inhibitor. | | Definition | ChEBI: Tesevatinib is a member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups at positions 4, 6 and 7, respectively. It is a multi-target tyrosine kinase inhibitor of EGFR, ErbB2, KDR, Flt4 and EphB4 and exhibits anti-cancer properties. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an epidermal growth factor receptor antagonist. It is a member of quinazolines, an aromatic ether, a member of monofluorobenzenes, a dichlorobenzene, a secondary amino compound, a diether and a tertiary amino compound. | | in vivo | Tesevatinib (XL-647) shows potent and long-lived inhibition of the WT EGFRin vivo. Tesevatinib (XL-647) substantially inhibits the growth of H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density[1]. | | IC 50 | EGFR: 0.3 nM (IC50); ErbB2: 16 nM (IC50); KDR: 1.5 nM (IC50); Flt-4: 8.7 nM (IC50) |
| | XL-647 Preparation Products And Raw materials |
|